Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Non-Current Liabilities (2019 - 2021)

Keros Therapeutics (KROS) has disclosed Total Non-Current Liabilities for 3 consecutive years, with $12.1 million as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Total Non-Current Liabilities rose 57.66% year-over-year to $12.1 million, compared with a TTM value of $12.1 million through Dec 2021, up 57.66%, and an annual FY2021 reading of $12.1 million, up 57.66% over the prior year.
  • Total Non-Current Liabilities was $12.1 million for Q4 2021 at Keros Therapeutics, up from $11.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $12.1 million in Q4 2021 and bottomed at $7.4 million in Q3 2020.
  • Average Total Non-Current Liabilities over 3 years is $9.4 million, with a median of $9.3 million recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities fell 25.93% in 2020, then soared 57.66% in 2021.
  • Year by year, Total Non-Current Liabilities stood at $10.3 million in 2019, then dropped by 25.93% to $7.7 million in 2020, then skyrocketed by 57.66% to $12.1 million in 2021.
  • Business Quant data shows Total Non-Current Liabilities for KROS at $12.1 million in Q4 2021, $11.5 million in Q3 2021, and $7.8 million in Q2 2021.